{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:54:20Z","timestamp":1793948060069,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2021-2-75"],"award-info":[{"award-number":["320.6750.2021-2-75"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Scientific and Technological Committee","award":["22S21902000"],"award-info":[{"award-number":["22S21902000"]}]},{"DOI":"10.13039\/501100020089","name":"Science and Technology Commission of Fengxian District, Shanghai Municipality","doi-asserted-by":"publisher","award":["2020SJ277"],"award-info":[{"award-number":["2020SJ277"]}],"id":[{"id":"10.13039\/501100020089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81793289"],"award-info":[{"award-number":["81793289"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. It has a wide range of clinical applications in various cancers and retinal diseases. The drugs entered the Chinese market by a large margin in 2017, and the user population changed to some extent. This study reevaluated the safety of bevacizumab through an analysis of the World Pharmacovigilance database (Food and Drug Administration Open Vigil 2.1) in conjunction with a comprehensive meta-analysis of RCTs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Real-world pharmacovigilance data originating from case reports were mined using Open Vigil and coded at the preferred term (PT) level using the Standardized MedDRA Query. Proportional reporting ratios (PRR) and reporting odds ratios (ROR) were used to detect safety signals. Eligible items were screened by searching PubMed, Wanfang, and Web of Science, and data were extracted for systematic review and meta-analysis using RevMan 5.4 software.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Analysis of the drug pharmacovigilance database revealed that the most significant PRRs were limb decortication syndrome (PRR\u2009=\u20092926), stomal varices (PRR\u2009=\u2009549), anastomotic (PRR\u2009=\u2009457) and ureteral fistula (PRR\u2009=\u2009406). Most safety signals at the PT level emerged as various types of injuries, toxicities, operational complications, systemic diseases, various reactions at the administration site, hematological and lymphatic disorders, and gastrointestinal disorders. Adverse reactions such as nasal septal perforation (PRR\u2009=\u200947.502), necrotizing fasciitis (PRR\u2009=\u200920.261), and hypertensive encephalopathy (PRR\u2009=\u200918.288) listed as rare in drug specifications should not be ignored with a high signal in the real world. A total of 8 randomized controlled trials (RCTs) were included in the meta-analysis, and the overall risk of adverse reactions following bevacizumab administration was relatively low, indicating a good safety profile (HR\u2009=\u20091.19, 95% CI:0.85\u2009~\u20091.65, <jats:italic>p<\/jats:italic>\u2009=\u20090.32).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The frequent adverse reactions of bevacizumab occurring in the real world are consistent with the data provided in RCTs and drug specifications. However, adverse reactions such as nasal septum perforation, necrotizing fasciitis, hypertensive encephalopathy and so on, listed as rare in drug specifications, may have a high signal of correlation in the real world, which all requires active monitoring and timely adjustment of bevacizumab posology during its clinical use.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40780-023-00314-w","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T13:02:26Z","timestamp":1704200546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials"],"prefix":"10.1186","volume":"10","author":[{"given":"Li","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8639-9689","authenticated-orcid":false,"given":"Zhenghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guorong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"314_CR1","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin(R)) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"314_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s40135-016-0091-2","volume":"4","author":"MR Thorell","year":"2016","unstructured":"Thorell MR, Goldhardt R. Update in the management of macular edema following retinal vein occlusions. Curr Ophthalmol Rep. 2016;4(1):38\u201347.","journal-title":"Curr Ophthalmol Rep"},{"key":"314_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.preteyeres.2017.10.006","volume":"63","author":"A Daruich","year":"2018","unstructured":"Daruich A, Matet A, Moulin A, Kowalczuk L, Nicolas M, Sellam A, et al. Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res. 2018;63:20\u201368.","journal-title":"Prog Retin Eye Res"},{"key":"314_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000320007","volume":"46","author":"U Schmidt-Erfurth","year":"2010","unstructured":"Schmidt-Erfurth U, Pollreisz A, Mitsch C, Bolz M. Antivascular endothelial growth factors in age-related macular degeneration. Dev Ophthalmol. 2010;46:21\u201338.","journal-title":"Dev Ophthalmol"},{"issue":"1","key":"314_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12885-022-10446-1","volume":"23","author":"LL Pang","year":"2023","unstructured":"Pang LL, Gan JD, Huang YH, Liao J, Zhuang WT, Ali WA, et al. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy. BMC Cancer. 2023;23(1):72.","journal-title":"BMC Cancer"},{"issue":"6","key":"314_CR6","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","volume":"24","author":"DF McDermott","year":"2018","unstructured":"McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749\u201357.","journal-title":"Nat Med"},{"issue":"2","key":"314_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1634\/theoncologist.2014-0330","volume":"20","author":"AA Brandes","year":"2015","unstructured":"Brandes AA, Bartolotti M, Tosoni A, Poggi R, Franceschi E. Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist. 2015;20(2):166\u201375.","journal-title":"Oncologist"},{"issue":"3","key":"314_CR8","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1345\/aph.1L426","volume":"43","author":"SMSS Gressett","year":"2009","unstructured":"Gressett SMSS. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43(3):490\u2013501.","journal-title":"Ann Pharmacother"},{"key":"314_CR9","doi-asserted-by":"publisher","first-page":"716648","DOI":"10.3389\/fped.2021.716648","volume":"9","author":"X Tang","year":"2021","unstructured":"Tang X, Xu X, Li J, Zhao B. Cardiotoxicity in biological agent-targeted therapy for rheumatoid arthritis: ADR signal mining and analysis of food and drug administration adverse event reporting system database. Front Pediatr. 2021;9:716648.","journal-title":"Front Pediatr"},{"issue":"4","key":"314_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s11096-018-0693-x","volume":"40","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Wang T, Li G, Sun S. Pharmacovigilance in China: development and challenges. Int J Clin Pharm. 2018;40(4):823\u201331.","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"314_CR11","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","volume":"11","author":"R B\u00f6hm","year":"2016","unstructured":"B\u00f6hm R, von Hehn L, Herdegen T, Klein HJ, Bruhn O, Petri H, H\u00f6cker J. OpenVigil FDA - inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLoS One. 2016;11(6):e0157753.","journal-title":"PLoS One"},{"key":"314_CR12","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Altman DG, Gtzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011:343:d5928.","DOI":"10.1136\/bmj.d5928"},{"key":"314_CR13","doi-asserted-by":"crossref","unstructured":"Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003\u201310.","DOI":"10.1001\/jamaoncol.2020.1024"},{"issue":"4","key":"314_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/oncolo\/oyab025","volume":"27","author":"M Lipsyc-Sharf","year":"2022","unstructured":"Lipsyc-Sharf M, Ou F, Yurgelun MB, Rubinson DA, Schrag D, Dakhil SR, Stella PJ, Weckstein DJ, Wender DB, Faggen M, Zemla TJ, Heying EN, Schuetz SR, Noble S, Meyerhardt JA, Bekaii-Saab T, Fuchs CS, Ng K. Cetuximab and irinotecan with or without bevacizumab in refractory metastatic colorectal cancer: BOND-3, an ACCRU network randomized clinical trial. Oncologist. 2022;27(4):292\u20138. https:\/\/doi.org\/10.1093\/oncolo\/oyab025.","journal-title":"Oncologist"},{"issue":"20","key":"314_CR15","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1001\/jama.2017.4568","volume":"317","author":"IU Scott","year":"2017","unstructured":"Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J, SCORE2 Investigator Group. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion the SCORE2 randomized clinical trial. JAMA. 2017;317(20):2072\u201387.","journal-title":"JAMA"},{"issue":"12","key":"314_CR16","doi-asserted-by":"publisher","first-page":"e183486","DOI":"10.1001\/jamaoncol.2018.3486","volume":"4","author":"C Gridelli","year":"2018","unstructured":"Gridelli C, de Castro CJ, Dingemans AC, Griesinger F, Grossi F, Langer C, et al. Safety and efficacy of bevacizumab plus standard-of-care treatment beyond disease progression in patients with advanced non-small cell lung cancer: the AvaALL randomized clinical trial. JAMA Oncol. 2018;4(12):e183486.","journal-title":"JAMA Oncol"},{"issue":"4","key":"314_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamaoncol.2017.5314","volume":"4","author":"C Cremolini","year":"2018","unstructured":"Cremolini C, Antoniotti C, Lonardi S, Aprile G, Falcone A. Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a randomized phase 2 clinical trial. JAMA Oncol. 2018;4(4):529\u201336.","journal-title":"JAMA Oncol"},{"issue":"4","key":"314_CR18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1634\/theoncologist.2018-0290","volume":"24","author":"AA Brandes","year":"2019","unstructured":"Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, Ghiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J. A Randomized Phase II Trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma. Oncologist. 2019;24(4):521\u20138.","journal-title":"Oncologist"},{"issue":"3","key":"314_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamaoncol.2020.6758","volume":"7","author":"H Akamatsu","year":"2021","unstructured":"Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N, et al. Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer previously treated with epidermal growth factor receptor-tyrosine kinase inhibitor: West Japan oncology group 8715L phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):386\u201394.","journal-title":"JAMA Oncol"},{"issue":"6","key":"314_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1530\/ERC-21-0239","volume":"29","author":"MH Kulke","year":"2022","unstructured":"Kulke MH, Ou FS, Niedzwiecki D, Huebner L, Kunz P, Kennecke HF, Wolin EM, Chan JA, O\u2019Reilly EM, Meyerhardt JA, Venook A. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocr Relat Cancer. 2022;29(6):335\u201344.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"314_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/JTO.0b013e3181f94ad4","volume":"6","author":"JD Hainsworth","year":"2011","unstructured":"Hainsworth JD, Fang L, Huang JE, Karlin D, Russell K, Faoro L, et al. BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab + carboplatin\/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol. 2011;6(1):109\u201314.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"314_CR22","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","volume":"22","author":"DH Johnson","year":"2004","unstructured":"Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184\u201391.","journal-title":"J Clin Oncol"},{"issue":"5","key":"314_CR23","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/1078-0432.CCR-16-1968","volume":"23","author":"R Kurzrock","year":"2017","unstructured":"Kurzrock R, Stewart DJ. Exploring the benefit\/risk associated with antiangiogenic agents for the treatment of non-small cell lung cancer patients. Clin Cancer Res. 2017;23(5):1137\u201348.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"314_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1871525715666170127101605","volume":"15","author":"S Riondino","year":"2017","unstructured":"Riondino S, Del Monte G, Fratangeli F, Guadagni F, Roselli M, Ferroni P. Anti-angiogenic drugs, vascular toxicity and thromboembolism in solid cancer. Cardiovasc Hematol Agents Med Chem. 2017;15(1):3\u20136.","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"6","key":"314_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.26442\/00403660.2020.06.000672","volume":"92","author":"KS Grechukhina","year":"2020","unstructured":"Grechukhina KS, Chebotareva NV, Krasnova TN. Nephrotoxicity of anti-angiogenesis drugs. Terapevticheskii Arkhiv. 2020;92(6):3\u20138.","journal-title":"Terapevticheskii Arkhiv"},{"key":"314_CR26","doi-asserted-by":"crossref","unstructured":"Izzedine H, Escudier B, Lhomme C, Pautier P, Rouvier P, Gueutin V, et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore). 2014;93(24):333-9.","DOI":"10.1097\/MD.0000000000000207"},{"issue":"1","key":"314_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13058-020-01258-x","volume":"22","author":"C Vaklavas","year":"2020","unstructured":"Vaklavas C, Roberts B, Varley KE, Lin NU, Liu MC, Rugo HS, et al. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2\/3 hormone receptor-positive and HER2-negative breast cancer. Breast Cancer Res. 2020;22(1):22.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"314_CR28","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1345\/aph.1L426","volume":"43","author":"SGS Shah","year":"2009","unstructured":"Shah SGS. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43(3):490\u2013501.","journal-title":"Ann Pharmacother"},{"issue":"10","key":"314_CR29","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/apt.16601","volume":"54","author":"TA Wichelmann","year":"2021","unstructured":"Wichelmann TA, Abdulmujeeb S, Ehrenpreis ED. Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database. Aliment Pharmacol Ther. 2021;54(10):1290\u20137.","journal-title":"Aliment Pharmacol Ther"},{"key":"314_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","volume":"182","author":"M Li","year":"2018","unstructured":"Li M, Kroetz DL. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152\u201360.","journal-title":"Pharmacol Ther"},{"issue":"11","key":"314_CR31","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1161\/01.ATV.17.11.2793","volume":"17","author":"JR Horowitz","year":"1997","unstructured":"Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, et al. Vascular endothelial growth factor\/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol. 1997;17(11):2793\u2013800.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"314_CR32","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1067\/mhj.2001.118471","volume":"142","author":"TD Henry","year":"2001","unstructured":"Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, et al. Endothelial growth factor to patients with coronary artery disease. Am Heart J. 2001;142:872\u201380.","journal-title":"Am Heart J"},{"issue":"10","key":"314_CR33","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1161\/01.CIR.0000061911.47710.8A","volume":"107","author":"TD Henry","year":"2003","unstructured":"Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107(10):1359\u201365.","journal-title":"Circulation"},{"issue":"7070","key":"314_CR34","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nature04479","volume":"438","author":"L Coultas","year":"2005","unstructured":"Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature. 2005;438(7070):937\u201345.","journal-title":"Nature"},{"key":"314_CR35","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"VJJ Eremina","year":"2008","unstructured":"Eremina VJJ, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129\u201336.","journal-title":"N Engl J Med"},{"issue":"4","key":"314_CR36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11912-012-0236-x","volume":"14","author":"JA Ramiscal","year":"2012","unstructured":"Ramiscal JA, Jatoi A. Nasal septal perforation from bevacizumab: a discussion of outcomes, management, and pharmacovigilance. Curr Oncol Rep. 2012;14(4):307\u201310.","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"314_CR37","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1517\/14740338.2014.960388","volume":"13","author":"M D'Amico","year":"2014","unstructured":"D\u2019Amico M, Pagano M, Pasa A, Puntoni M, Clavarezza M, Gennari A, et al. An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab. Expert Opin Drug Saf. 2014;13(11):1437\u201342.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"314_CR38","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3109\/0284186X.2010.537692","volume":"50","author":"JA Ramiscal","year":"2011","unstructured":"Ramiscal JA, Jatoi A. Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients. Acta Oncol. 2011;50(4):578\u201381.","journal-title":"Acta Oncol"},{"issue":"6","key":"314_CR39","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/sj.bjc.6605828","volume":"103","author":"A Mailliez","year":"2010","unstructured":"Mailliez A, Baldini C, Van JT, Servent V, Mallet Y, Bonneterre J. Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients. Br J Cancer. 2010;103(6):772\u20135.","journal-title":"Br J Cancer"},{"key":"314_CR40","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1471-2334-14-198","volume":"4","author":"T Ugai","year":"2014","unstructured":"Ugai T, Norizuki M, Mikawa T, Ohji G, Yaegashi M. Necrotizing fasciitis caused by Haemophilus influenzae type b in a patient with rectal cancer treated with combined bevacizumab and chemotherapy: a case report. BMC Infect Dis. 2014;4:198.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"314_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1086\/516908","volume":"25","author":"M Stumvoll","year":"1997","unstructured":"Stumvoll M, Fritsche A. Necrotizing fasciitis caused by unencapsulated Haemophilus influenzae. Clin Infect Dis. 1997;25(2):327.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"314_CR42","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1128\/CVI.05675-11","volume":"19","author":"EB Nix","year":"2012","unstructured":"Nix EB, Hawdon N, Gravelle S, Biman B, Brigden M, Malik S, et al. Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era. Clin Vaccine Immunol. 2012;19(5):766\u201371.","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"314_CR43","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1093\/cid\/ciaa875","volume":"73","author":"HM Soeters","year":"2021","unstructured":"Soeters HM, Oliver SE, Plumb ID, Blain AE, Zulz T, Simons BC, et al. Epidemiology of invasive haemophilus influenzae serotype a disease-United States, 2008\u20132017. Clin Infect Dis. 2021;73(2):e371\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"314_CR44","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4103\/0253-7613.125195","volume":"46","author":"MAAS Sendur","year":"2014","unstructured":"Sendur MAAS, \u00d6zdemir NY, Zengin N. Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma. Indian J Pharmacol. 2014;46(1):125\u20136.","journal-title":"Indian J Pharmacol"},{"issue":"50","key":"314_CR45","doi-asserted-by":"publisher","first-page":"82473","DOI":"10.18632\/oncotarget.12666","volume":"7","author":"H Zhang","year":"2016","unstructured":"Zhang H, Huang Z, Zou X, Liu T. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2016;7(50):82473\u201381.","journal-title":"Oncotarget"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-023-00314-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-023-00314-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-023-00314-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T13:16:43Z","timestamp":1704201403000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-023-00314-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["314"],"URL":"https:\/\/doi.org\/10.1186\/s40780-023-00314-w","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"14 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}